Psychiatr. pro Praxi, 2005; 5: 233-236

PHARMACOTHERAPEUTIC OPTIONS IN DEPRESSION

prof. MUDr. Eva Češková CSc
Psychiatrická klinika LF MU a FN Brno

The importance of antidepressants for the further development of psychiatry is summarized. In more details 2 groups of antidepressants, e.g. specific antidepressant influencing preferentially serotonin or norepinephrine/dopamine and dual antidepressants are discussed. New indication within depressive disorder – targeted treatment of depression according to prevalence of symptoms, residual symptoms and breakthrough of pharmacoresistance are discussed. Because the specific antidepressants are well tolerated and safe, the indications are widened also outside the range of depressive disorders.

Keywords: Key words: specific antidepressants, dual acting antidepressants, target symptoms, residual symptoms, breakthrough of pharmacoresistance, indication.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. PHARMACOTHERAPEUTIC OPTIONS IN DEPRESSION. Psychiatr. praxi. 2005;9(5):233-236.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allgulander CH, Haciett D, Salina E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder. Br J Psychiatry 2001; 179: 15-22. Go to original source... Go to PubMed...
    2. Carpenter LL, Jocic Z, Hall JM et al.: Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999; 60: 45-49. Go to original source... Go to PubMed...
    3. Delgado P, Moreno F. Antidepressants and the brain. Int Clin Psychopharmacol 1999; 14: suppl.1, S9-S16. Go to original source... Go to PubMed...
    4. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 1, 2005 - v tisku. Go to original source... Go to PubMed...
    5. Fava M, Davison KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179-200. Go to original source... Go to PubMed...
    6. Franchini L, Zanardi R, Gasperini M, Smeraldi E. Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate. J Clin Psychiat 1999; 60: 861-865. Go to original source... Go to PubMed...
    7. Frank E, Kupfer DJ, Perel JM et al. Comparison of full dose versus half dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993; 27: 139-145. Go to original source... Go to PubMed...
    8. Heretik A et al. EPID Epidemiológia depresie na Slovensku. Nové Zámky: Psychoprof 2003; 200s.
    9. Keller MB, Lavori PW, Mueller TI et al. Time to recovery, chronicity, and levels of psychopathology in major depression. Arch Gen Psychiatr 1992; 49: 809-816. Go to original source... Go to PubMed...
    10. Lepine JP, Gasstpar M, Mendlewicz J et al. Depression in the comunity the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12: 19-29. Go to original source... Go to PubMed...
    11. Kupfer DJ, Frank E, Perel JM et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiat 1992; 49: 769-773. Go to original source... Go to PubMed...
    12. Ithak WW, Rapaport MH, Gotto JG. The effectiveness of atypical antipsychotic medications in depressive disorders. Curr Psychiatry Rep 2004; 6: 422-424. Go to original source... Go to PubMed...
    13. Liebowitz MR, Gelenberg AJ, Munjack D.: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry, 62, 2005; 190-198. Go to original source... Go to PubMed...
    14. Melartin TK, Rytsala HJ, Leskla US et al. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depression. J Clin Psychiatry 2004; 65: 810-819. Go to original source... Go to PubMed...
    15. Moller H.-J. Therapieresistenz auf Antidepresiva. Der Nervenarzt 2004; 5: 499-517. Go to original source... Go to PubMed...
    16. Mueller TI, Leon AC, Keller MB et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiat 1999; 156: 1000-1006. Go to original source...
    17. Nelson JC. Augmentation strategies with serotoninergic-noradrenergic combinations. J Clin Psychiatry 1998; 59: 65-68.
    18. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51: 39-47.
    19. Nierenberg AA, Keefe BR, Leslie VC et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60: 221-225. Go to original source... Go to PubMed...
    20. Sanz RJ, De-las-Cuevas C, Kiuru A et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365: 451-453. Go to original source...
    21. Stahl SM. Essentials psychopharmacology. 2nd edition Cambridge University Press, 2000.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.